{
    "matches": [
        {
            "Extracted_claim": {
                "subject": {
                    "study": "An X et al.",
                    "year": "2010",
                    "sample size": "89",
                    "proportion of patients with pretreatment NLR >5": "16 (17.9%)",
                    "overall survival comparison (NLR >5 vs. \u22645)": "2.4 versus 7.7 months",
                    "hazard ratio (NLR \u22645 was set at 1)": "HR = 4.49",
                    "P-value": "0.013",
                    "association": "elevated NLR as independent prognostic factor for OS in APC patients receiving chemotherapy"
                },
                "measures": "[hazard ratio, P-value]",
                "outcomes": "[4.49, 0.013]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Study": "An X et al.",
                    "Year": "2010",
                    "number of patients": "89",
                    "Number of patientis with NLR > 5 (%)": "16 (17.9)",
                    "Overall survival (NLR >5 vs \u22645) (months)": "2.4 versus 7.7",
                    "NLR \u22645": "1"
                },
                "measures": "[Hazard Ratio, P-Value]",
                "outcomes": "[4.49, 0.013]"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study": "Wang DS et al.",
                    "year": "2012",
                    "sample size": "86",
                    "proportion of patients with pretreatment NLR >5": "12 (13.9%)",
                    "overall survival comparison (NLR >5 vs. \u22645)": "5.8 versus 10.2 months",
                    "association": "elevated NLR as independent prognostic factor for OS in APC patients receiving chemotherapy"
                }
            },
            "Ground_truth_claim": {
                "subject": {
                    "Study": "Wang DS et al.",
                    "Year": "2012",
                    "number of patients": "86",
                    "Number of patientis with NLR > 5 (%)": "12 (13.9)",
                    "Overall survival (NLR >5 vs \u22645) (months)": "5.8 versus 10.2",
                    "NLR \u22645": "1"
                },
                "measures": "[]",
                "outcomes": "[]"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study": "Stotz M et al.",
                    "year": "2013",
                    "sample size": "261",
                    "proportion of patients with pretreatment NLR >5": "79 (30.3%)",
                    "hazard ratio (NLR \u22645 was set at 1)": "HR = 2.53",
                    "P-value": "<0.01",
                    "association": "elevated NLR as independent prognostic factor for OS in APC patients receiving chemotherapy",
                    "study design": "pooled data from patients receiving chemotherapy (n = 179) and no chemotherapy (n = 82)"
                },
                "measures": "[hazard ratio, P-value]",
                "outcomes": "[2.53, <0.01]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Study": "Stotz M et al.",
                    "Year": "2013",
                    "number of patients": "261",
                    "number of patients who received chemotherapy": "179",
                    "number of patients who did not received chemotherapy": "82",
                    "Number of patientis with NLR > 5 (%)": "79 (30.3)",
                    "Overall survival (NLR >5 vs \u22645) (months)": "NA",
                    "NLR \u22645": "1"
                },
                "measures": "[Hazard Ratio, P-Value]",
                "outcomes": "[2.53, <0.01]"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study": "Our study",
                    "year": "2013",
                    "sample size": "253",
                    "proportion of patients with pretreatment NLR >5": "40 (15.8%)",
                    "overall survival comparison (NLR >5 vs. \u22645)": "6.0 versus 12.8 months",
                    "hazard ratio (NLR \u22645 was set at 1)": "HR = 1.95",
                    "P-value": "<0.01",
                    "association": "elevated NLR as independent prognostic factor for OS in APC patients receiving chemotherapy"
                },
                "measures": "[hazard ratio, P-value]",
                "outcomes": "[1.95, <0.01]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Study": "Our study",
                    "Year": "2013",
                    "number of patients": "253",
                    "Number of patientis with NLR > 5 (%)": "40 (15.8)",
                    "Overall survival (NLR >5 vs \u22645) (months)": "6.0 versus 12.8",
                    "NLR \u22645": "1"
                },
                "measures": "[Hazard Ratio, P-Value]",
                "outcomes": "[1.95, <0.01]"
            },
            "match": "yes"
        }
    ],
    "total_extracted_claims": 4,
    "total_ground_truth_claims": 4,
    "number_of_matches": 4
}